

Below is a reference list of the *Drugs* articles used as a source of clinical trials in “Efficacy of Xanthine Oxidase Inhibitors in Lowering Serum Urate Acid (SUA): A systematic review and meta-analysis.”¹⁻⁶

1. Cicero AFG, Pirro M, Watts GF, Mikhailidis DP, Banach M, Sahebkar A. Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. *Drugs*. Jan 2018;78(1):99-109. doi:10.1007/s40265-017-0839-5
2. Heel RC, Brogden RN, Speight TM, Avery GS. Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia. *Drugs*. Nov 1977;14(5):349-66. doi:10.2165/00003495-197714050-00002
3. Frampton JE. Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout. *Drugs*. Mar 2015;75(4):427-38. doi:10.1007/s40265-015-0360-7
4. Hoy SM. Lesinurad: First Global Approval. *Drugs*. Mar 2016;76(4):509-16. doi:10.1007/s40265-016-0550-y
5. Lyseng-Williamson KA. Pegloticase: in treatment-refractory chronic gout. *Drugs*. Nov 12 2011;71(16):2179-92. doi:10.2165/11202830-000000000-00000
6. Oldfield V, Perry CM. Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia. *Drugs*. 2006;66(4):529-45. doi:10.2165/00003495-200666040-00008